BioMedicure

BioMedicure is a clinical-stage biotechnology company dedicated to the development of next-generation cancer immunotherapies, with a primary focus on CAR-T and TCR-T cell therapies. The company utilizes its proprietary platforms to engineer multi-target and universal cell products designed to overcome the limitations of current treatments in both hematological and solid tumors. BioMedicure's pipeline features several promising candidates, including dual-target CAR-T therapies for B-cell malignancies and novel treatments for GPC3-positive liver cancer and Claudin 18.2-positive gastric cancers. Headquartered in San Diego with significant research and manufacturing facilities in China, the company integrates global resources to advance precision medicine. Their approach emphasizes high specificity and reduced toxicity to improve patient outcomes in oncology. The company also explores small molecule candidates to complement its cell therapy portfolio.